1Clinical Pipeline

2Emerging pipeline

Transforming Drug Discovery for the Next Wave of Medicines

BXCL701 Revolutionizing drug development and translation research in Immuno-Oncology (IO)

BXCL501 Treating the Symptoms of Neuropsychiatric and Neurodegenerative Diseases

BXCL702 Developing the drug as mono-therapy and in combination with immune-checkpoint inhibitors

Learn more

The Healing Power of Science

Medicines that change lives

Bioxcel

Targeting

Targeting immuno-oncology and neuroscience disorders with significant unmet medical need

Bioxcel

Re-Innovation

Proprietary drug re-innovation approach to other underserved areas in oncology and neuroscience

Bioxcel

Higher Probability

Generating first in class drug candidates with a higher probability of clinical and regulatory success

Bioxcel

Therapeutic Benefit

Potential to provide significant therapeutic benefit to the patients who need close medical attention

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.

bioexcel

Press Coverage

bioexcel
21 April 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

View all Press Coverages

News Releases

bioexcel
13 November 2017

New Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate BXCL701 in Combination with NKTR-214 in Multiple Oncology Indications

View all News Releases